NVCT NASDAQ
Nuvectis Pharma, Inc.
1W: -2.4%
1M: -8.6%
3M: -6.7%
YTD: +117.3%
1Y: +207.7%
3Y: +103.9%
$18.44
-0.05 (-0.27%)
After Hours: $19.59 (+1.15, +6.24%)
Weekly Expected Move ±9.8%
$16
$18
$20
$22
$24
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -21.73.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$1.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$603.6M
52W Range5.55-29.28
Volume318,829
Avg Volume284,699
Beta-0.24
Dividend—
Analyst Ratings
Company Info
CEORon Bentsur
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-04
Websitenuvectis.com
1 Bridge Plaza
Fort Lee, NJ 07024
US
Fort Lee, NJ 07024
US
201 614 3150
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Latest News
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Average Price Target of $36.25
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – What’s Next?
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Carson Michael J. | A-Award | 30,000 | — | 2026-08-03 |
| BENTSUR RON | P-Purchase | 12,500 | $20.00 | 2026-06-30 |
| Mosseri Marlio Charl | P-Purchase | 50,000 | $18.32 | 2026-06-30 |
| Hoberman Kenneth | A-Award | 35,000 | — | 2026-06-11 |
| Oliviero James F III | A-Award | 35,000 | — | 2026-06-11 |